These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30145841)

  • 1. Movement disorder society criteria for clinically established early Parkinson's disease.
    Berg D; Adler CH; Bloem BR; Chan P; Gasser T; Goetz CG; Halliday G; Lang AE; Lewis S; Li Y; Liepelt-Scarfone I; Litvan I; Marek K; Maetzler C; Mi T; Obeso J; Oertel W; Olanow CW; Poewe W; Rios-Romenets S; Schäffer E; Seppi K; Heim B; Slow E; Stern M; Bledsoe IO; Deuschl G; Postuma RB
    Mov Disord; 2018 Oct; 33(10):1643-1646. PubMed ID: 30145841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the MDS clinical diagnostic criteria for Parkinson's disease.
    Postuma RB; Poewe W; Litvan I; Lewis S; Lang AE; Halliday G; Goetz CG; Chan P; Slow E; Seppi K; Schaffer E; Rios-Romenets S; Mi T; Maetzler C; Li Y; Heim B; Bledsoe IO; Berg D
    Mov Disord; 2018 Oct; 33(10):1601-1608. PubMed ID: 30145797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New Diagnostic Criteria for Parkinson's Disease: MDS-PD Criteria].
    Watanabe H; Hara K; Ito M; Katsuno M; Sobue G
    Brain Nerve; 2018 Feb; 70(2):139-146. PubMed ID: 29433115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDS clinical diagnostic criteria for Parkinson's disease.
    Postuma RB; Berg D; Stern M; Poewe W; Olanow CW; Oertel W; Obeso J; Marek K; Litvan I; Lang AE; Halliday G; Goetz CG; Gasser T; Dubois B; Chan P; Bloem BR; Adler CH; Deuschl G
    Mov Disord; 2015 Oct; 30(12):1591-601. PubMed ID: 26474316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts.
    Pilotto A; Heinzel S; Suenkel U; Lerche S; Brockmann K; Roeben B; Schaeffer E; Wurster I; Yilmaz R; Liepelt-Scarfone I; von Thaler AK; Metzger FG; Eschweiler GW; Postuma RB; Maetzler W; Berg D
    Mov Disord; 2017 Jul; 32(7):1025-1034. PubMed ID: 28509336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A population-based 10-year study.
    Mahlknecht P; Gasperi A; Djamshidian A; Kiechl S; Stockner H; Willeit P; Willeit J; Rungger G; Poewe W; Seppi K
    Mov Disord; 2018 Mar; 33(3):405-413. PubMed ID: 29436728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort.
    Fereshtehnejad SM; Montplaisir JY; Pelletier A; Gagnon JF; Berg D; Postuma RB
    Mov Disord; 2017 Jun; 32(6):865-873. PubMed ID: 28429825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Diagnostic Accuracy of Parkinson's Disease: Where Do We Stand?
    Virameteekul S; Revesz T; Jaunmuktane Z; Warner TT; De Pablo-Fernández E
    Mov Disord; 2023 Apr; 38(4):558-566. PubMed ID: 36602274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases.
    Malek N; Lawton MA; Grosset KA; Bajaj N; Barker RA; Ben-Shlomo Y; Burn DJ; Foltynie T; Hardy J; Morris HR; Williams NM; Wood N; Grosset DG;
    Parkinsonism Relat Disord; 2017 Jul; 40():40-46. PubMed ID: 28431829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDS clinical diagnostic criteria for Parkinson's disease in China.
    Li J; Jin M; Wang L; Qin B; Wang K
    J Neurol; 2017 Mar; 264(3):476-481. PubMed ID: 28025665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing.
    Barton BR; Bernard B; Czernecki V; Goldman JG; Stebbins G; Dubois B; Goetz CG
    Mov Disord; 2014 Sep; 29(10):1252-7. PubMed ID: 24821679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community.
    Mahlknecht P; Gasperi A; Willeit P; Kiechl S; Stockner H; Willeit J; Rungger G; Sawires M; Nocker M; Rastner V; Mair KJ; Hotter A; Poewe W; Seppi K
    Mov Disord; 2016 Sep; 31(9):1405-8. PubMed ID: 27273736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective assessment of movement disorder society criteria for mild cognitive impairment in Parkinson's disease.
    Loftus AM; Bucks RS; Thomas M; Kane R; Timms C; Barker RA; Gasson N
    J Int Neuropsychol Soc; 2015 Feb; 21(2):137-45. PubMed ID: 25666735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the Movement Disorder Society prodromal criteria in healthy G2019S-LRRK2 carriers.
    Mirelman A; Saunders-Pullman R; Alcalay RN; Shustak S; Thaler A; Gurevich T; Raymond D; Mejia-Santana H; Orbe Reilly M; Ozelius L; Clark L; Gana-Weisz M; Bar-Shira A; Orr-Utreger A; Bressman SB; Marder K; Giladi N;
    Mov Disord; 2018 Jul; 33(6):966-973. PubMed ID: 29603409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale.
    Goetz CG; Liu Y; Stebbins GT; Wang L; Tilley BC; Teresi JA; Merkitch D; Luo S
    Mov Disord; 2016 Dec; 31(12):1865-1873. PubMed ID: 27943473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort.
    Kang UJ; Goldman JG; Alcalay RN; Xie T; Tuite P; Henchcliffe C; Hogarth P; Amara AW; Frank S; Rudolph A; Casaceli C; Andrews H; Gwinn K; Sutherland M; Kopil C; Vincent L; Frasier M
    Mov Disord; 2016 Jun; 31(6):924-32. PubMed ID: 27113479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Azevedo P; Ferreira J; Abreu D; Gonçalves N; Nunes RG; Campos J; Ferreira JJ
    Mov Disord; 2015 Jun; 30(7):953-9. PubMed ID: 25758364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial.
    Lipsmeier F; Taylor KI; Kilchenmann T; Wolf D; Scotland A; Schjodt-Eriksen J; Cheng WY; Fernandez-Garcia I; Siebourg-Polster J; Jin L; Soto J; Verselis L; Boess F; Koller M; Grundman M; Monsch AU; Postuma RB; Ghosh A; Kremer T; Czech C; Gossens C; Lindemann M
    Mov Disord; 2018 Aug; 33(8):1287-1297. PubMed ID: 29701258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
    Fox SH; Katzenschlager R; Lim SY; Barton B; de Bie RMA; Seppi K; Coelho M; Sampaio C;
    Mov Disord; 2018 Aug; 33(8):1248-1266. PubMed ID: 29570866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease.
    Friedman JH; Alves G; Hagell P; Marinus J; Marsh L; Martinez-Martin P; Goetz CG; Poewe W; Rascol O; Sampaio C; Stebbins G; Schrag A
    Mov Disord; 2010 May; 25(7):805-22. PubMed ID: 20461797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.